The nuclear medicine market is projected to reach $54.7 billion by 2032

From GlobeNewswire: 2025-01-08 05:30:00

The nuclear medicine market reached $13.6 billion in 2023, projected to grow at a CAGR of 16.3% from 2024 to 2032 due to the increasing incidence of cancer and cardiovascular diseases, demand for non-invasive diagnostic techniques, and innovation in radiopharmaceuticals. Investments in research and development aim to enhance healthcare infrastructure, broaden diagnostic access, and improve public health outcomes, particularly in developed countries.
The market is divided into diagnostics and therapeutics, with the diagnostics segment generating $9.4 billion in revenue in 2023. Nuclear imaging methods, like myocardial perfusion imaging, play a crucial role in cardiology as heart disease prevalence rises globally. Hospitals are the dominant end-user segment, with a projected revenue of $33.3 billion by 2032, primarily driven by investments in advanced imaging technologies and specialized nuclear medicine professionals.
In North America, the nuclear medicine market accounted for $7 billion in revenue in 2023, with a forecasted CAGR of 15.6% through 2032. The region’s advanced healthcare infrastructure facilitates the adoption of nuclear imaging technologies, especially hybrid imaging systems, to meet the increasing demand for nuclear diagnostics for early detection and personalized treatment strategies.
Major players in the nuclear medicine market include Actinium Pharmaceuticals, Boston Scientific, Bracco, Cardinal Health, Curium Pharma, GE Healthcare, and Novartis. The industry insights cover various aspects such as industry ecosystem analysis, growth drivers, challenges, regulatory landscape, reimbursement scenario, technology landscape, future market trends, and more, providing comprehensive information for strategic decision-making in the nuclear medicine sector.



Read more at GlobeNewswire: Nuclear Medicine Market to hit USD 54.7 billion by 2032,